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Abstract
Introduction: Adult Growth hormone Deficiency is a well known phenomenon effecting both males and females.
Adult Growth Hormone Deficiency is marked by a number of neuropsychiatric, cognitive performance, cardiac,
metabolic, muscular, and bone symptoms and clinical features. There is no known standardized acceptable
therapeutic modality to treat this condition. A recent meta-analysis found that after 16 years of Growth Hormone
replacement therapy a large proportion of the patients still had Growth Hormone associated symptoms especially
related to executive functioning. A major goal is to increase plasma levels of both insulin-like growth factor
(insulin-like growth factor-1) and insulin-like growth factor binding protein 3.
Case Presentation: We report a case of a 45-year-old caucasian woman with early ovarian failure for 2 years and
amenorrhea since the age of 43, who presented with Adult Growth Hormone Deficiency and an IGF-1 of 126 ng/mL.
Since her insulin-like growth factor-1 was lowest at 81 ng/mL, she was started on insulin-like growth factor-1 Increlex at
0.2 mg at bedtime, which immediately raised her insulin-like growth factor-1 levels to 130 ng/mL within 1 month, and
193 ng/mL, 249 ng/mL, and 357 ng/mL, after 3, 4, and 5 months, respectively, thereafter. Her insulin-like growth factor
binding protein 3 continued to decrease. It was at this point when we added back the Growth Hormone and increased
her Increlex dosage to 1.3 - 1.5 mg that her insulin-like growth factor binding protein 3 began to increase.
Conclusion: It appears that in some patients with Adult Growth Hormone Deficiency, insulin-like growth factor-1
elevation is resistant to direct Growth Hormone treatment. Furthermore, the binding protein may not rise with
insulin-like growth factor-1. However, a combination of Growth Hormone and insulin-like growth factor-1 treatment
may be a solution.
Introduction
Adult Growth Hormone Deficiency (AGHD) is a well
known phenomenon effecting both males and females.
AGHD is marked by a number of neuropsychiatric, cog-
nitive performance, cardiac, metabolic, muscular, and
bone symptoms and clinical features [1]. In one study it
was found that after one year of growth hormone (GH)
replacement therapy in ovarian cancer patients among
others, the mean value of all tumor markers remained
within the normal range and there was no significant
increase within the normal range either. This finding
was accompanied by an increase of insulin-like growth
factor (IGF-1) plasma levels [2].
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always resulted in consistent increases of IGF-1 in
AGHD patients. The mechanism of this inconsistency
has been studied by De Gennaro et al. [3]. In a series of
experiments they investigated the effect of thyroid hor-
mone deficiency and GH treatment on hypothalamic
GH-releasing hormone (GHRH)/somatostatin (SS) con-
centrations, GHRH/SS mRNA levels, and plasma GH
and somatomedin-C (IGF-1) concentrations in rats
made deficient by exposing dams with propylthiouracil
in the drinking water since the day of parturition. Treat-
ment of hypothyroid rats with GH for 14 days comple-
tely restored hypothalamic GHRH content and reversed
the increase in GHRH mRNA, but did not alter plasma
IGF-1 concentrations. These data indicate that, in
hypothyroid rats, the changes in hypothalamic GHRH
content and gene expression are due to the GH defi-
ciency ensuing from the hypothyroid state. Failure of
the GH treatment to increase plasma IGF-1 indicates
that the feedback regulation on GHRH neurons is oper-
ated by circulating GH and/or perhaps tissue but not
plasma IGF-1 concentrations. Presence of low plasma
IGF-1 concentrations would be directly related to thyr-
oid hormone deficiency in this case but consistent
methods for augmenting its levels in AGHD are unfor-
tunately lacking. There is no known standardized accep-
table therapeutic modality to treat this condition.
While there is a plethora of literature from meta-ana-
lysis showing the medical benefits of GH replacement
therapy in cardiovascular disease, cancer risk, HIV, bone
mineral density, fibromyalgia, head trauma, brain pro-
cessing speed among others [3-10], there remains con-
troversy as to what actually constitutes AGHD.
Previously, a number of hormonal test levels had to
be lowered or raised as new research supported specific
level changes (that is, PTH, TSH). In adults, a similar
problem has arisen for an appropriate reference stan-
dard for IGF-1 and AGHD. Falletti et al. [3] in their
meta-analysis suggested that the notion of IGF-1 plasma
levels to be an independent diagnostic marker in
AGHD is controversial. Many endocrinology studies
link low IGF-1 plasma levels with low levels of other
anterior pituitary hormones, that is, LH, FSH, and TSH
[11]. It is noteworthy that low IGF-1 between 84 and
100 u/l with other anterior pituitary deficiencies has
been considered sufficient evidence for GH therapy.
However, we recently reported that IGF-1 deficiencies
occur independently of comorbid deficiencies of LH,
FSH, and TSH [12].
We report on a case where a woman with early ovar-
ian failure, accompanied by seemingly low IGF-1 plasma
levels, had severe comorbid symptoms which worsened
as her IGF-1 levels continued to fall independent of
anterior pituitary hormone deficiency assessment. We
show that a combination of GH and IGF-1 replacement
therapy to increase both IGF-1 and IGF-BP3 plasma
levels may indeed be an important novel therapeutic
modality to treat AGHD independent of targeting ante-
rior pituitary hormone deficiencies.
Case presentation
A 45-year-old Caucasian woman with early ovarian fail-
ure of two years duration came to our clinic. She was
diagnosed with AGHD with a IGF-1 plasma level of 126
ng/mL. At entrance to our program she was on Human
Growth Hormone at a dosage of 0.2 mg. Follow-up
blood analysis revealed that instead of rising, her IGF-1
level continued to fall and she felt her symptoms wor-
sening. These symptoms included abdominal distention
and bloating, sleeping problems, depression, nervous-
ness, loss of muscle mass, decreased bone density and
weight change (increase). Interestingly, her IGF-BP3
level was also low.
During the course of treatment, following treatment
with Norditropin® (somatropin (rDNA origin)) by injec-
tion at 0.45 mg, her GH level continued to drop. The
dosage level was increased to 0.6 to 0.7 mg and she
experienced rapid weight gain. At that point the dosage
level was decreased to 0.5 mg. Subsequent to this treat-
ment we determined that while her IGF-1 level
increased, her IGF-BP3 level decreased and her symp-
toms worsened, especially the rapid weight gain. The
Norditropin® regimen was terminated on 6 August 2009.
On 6 May 2009, we found that her IGF-1 plasma level
was at a low level of 81 ng/ml. (see Figure 1).
At this juncture one of us (ERB) considered the use of
Increlex® (a mecasermin (rDNA origin) injection). This
agent is an aqueous solution for injection containing
human insulin-like growth factor-1 (rhIGF-1) produced
by recombinant DNA technology. IGF-1 consists of 70
amino acids in a single chain with three intramolecular
disulfide bridges and a molecular weight of 7649 dal-
tons. The amino acid sequence of the product is identi-
cal to that of endogenous human IGF-1. The rhIGF-1
protein is synthesized in bacteria (Escherichia coli)t h a t
have been modified by the addition of the gene for
human IGF-1. This agent was started at 0.2 mg at bed-
time which we found to raise her IGF-1 level to 130 ng/
ml within one month and, as observed in Figure 1,
increased by 6 August 2009 to 193 ng/ml, then to 249
ng/ml on 5 September 2009, and finally on 1 January
2010 it was at a high of 395 ng/ml. Surprisingly her
IGF-BP3 plasma levels continued to decrease to 2.5 ng/
ml. On 23 November 2009 we re-administered Nordi-
tropin® in combination with an increased amount of
Increlex® between 1.3 and 1.5 mg. Subsequent to this
treatment while her IGF-1 level was maintained at a
high level (373 to 395 ng/ml) her IGF-BP3 began to
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observed in Figure 2.
Following this novel combined treatment we observed
an improvement in both physiological and neuropsy-
chiatric symptoms.
Discussion
Adult Growth Hormone Deficiency (AGHD) is marked by
a number of neuropsychiatric, cardiac, metabolic, muscu-
lar, bone symptoms and clinical features. The most
common of these are increased body fat (particularly
Figure 1 IGF-1 (Somatomedin-C). Reference range: 94 to 267 ng/mL.
Figure 2 IGF-BP3. Reference range: 3.4 to 7.0 ng/mL.
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cle) and functional strength, thin skin and cool extremities,
decreased psychological well-being and energy, reduced
bone density, an increase in c-reactive protein, low-density
lipoprotein (LDL), fibrinogen, and plasminogen activator
inhibitor-1 (PAI-1), a decrease in high-density lipoprotein
(HDL), decreased insulin sensitivity, and decreased quality
of life [13].
It appears that in some patients with AGHD, IGF-1
elevation is resistant to direct GH treatment. The inter-
action of IGF-1 and IGF-BP3 is quite complex but
seems to involve the integrity of the GH receptor. Pre-
vious work from Wilson’s laboratory has shown that the
constant subcutaneous infusion of IGF-1 to monkeys
with normal pituitary glands results in a sustained eleva-
tion in circulating concentrations of IGF-BP3, whereas
the acute administration of IGF-1 to monkeys pretreated
with a GH receptor antagonist produces a brief, but sig-
nificant, elevation in serum IGF-BP3. Experiments from
Wilson’s group indicate that IGF-1 administration dur-
ing GH receptor antagonism restores circulating levels
of IGF-BP3. It remains to be determined whether IGF-1
directly affects hepatic synthesis and secretion of IGF-
BP3 [14]. Therefore the use of IGF-1 alone may not be
enough to raise IGF-BP3 levels but in combination with
GH receptor agonistic activity it may induce the
increases we observed herein.
Finally, we reported earlier from our laboratory [13]
on the benefits of increasing low IGF-1 plasma levels to
normal values. These benefits, which are consistent with
literature findings [15], include an increase of IGF-1
levels to the high normal range; reverses of CMD and
BMD from 138.1 to 279.4; fibromyalgia patients showed
significant improvement with IGF-1 level of 98.6 to
173.3; brain processing speed and memory improved
with IGF-1 levels of 150 to 250; 100-point increase of
IGF-1 levels associated with seven-point increases in I.
Q.; an IGF-1 elevation of 74.0 to 362.6 in head trauma
patients; improved anxiety, depression, and short/long
term memory; improvement in cognitive function from
135 to 213; reduced carotid intimal media thickness
from 51.8 to 234.4; improvement in insulin sensitivity
IGF-1 levels of 103.5 to 231.1; and reduction of abdom-
inal fat accumulation occurring with the increase of
IGF-1 from 146 to 267.
Conclusion
The IGF-BP3 binding protein may not rise with IGF-1
treatment alone. The need for both IGF-1 and IGF-
BP3 plasma levels to rise especially in cases with
AGHD as seen in the case presented herein is ade-
quately supported in the literature. Impairment of this
complex system may be overcome by the combination
of both GH (using Norditropin®) and IGF-1 (using
Increlex®) and must await further confirmation in a
large population.
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